Ad
related to: gilead sciences
Search results
Gilead progresses subject enrolment in HIV prevention trials
Clinical Trials Arena via Yahoo Finance· 6 hours agoGilead Sciences has announced the progression of subject enrolment in two Phase II collaborative...
... and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis - Gilead ...
Benzinga· 9 hours agoGilead Sciences, Inc. GILD, following the recent acquisition of CymaBay Therapeutics, Inc., today announced two-year interim results from the ongoing ASSURE ...
Vir pressures Gilead with hepatitis D cocktail showing early efficacy in phase 2
FierceBiotech· 2 hours agoVir Biotechnology's hepatitis D combination therapy has shown early efficacy in results from a phase...
The Zacks Analyst Blog Highlights NextEra Energy, BP, Gilead Sciences, Hamilton Beach and FONAR
Zacks via Yahoo Finance· 1 day agoStocks recently featured in the blog include: NextEra Energy, Inc. NEE, BP p.l.c. BP, Gilead ...
Paulson Wealth Management Inc. Grows Stake in Gilead Sciences, Inc. (NASDAQ:GILD)
ETF DAILY NEWS· 2 days agoPaulson Wealth Management Inc. grew its position in Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 5.3% in the 4th quarter, according to its most ...
J&J seeks expanded approvals for paediatric HIV-1 therapy
Pharmaceutical Technology via Yahoo Finance· 7 hours agoA Phase II/III clinical trial by Gilead Sciences has established the efficacy, safety and...
... Is Arcus Biosciences Stock Trading Higher Today? - Arcus Biosciences (NYSE:RCUS), Gilead ...
Benzinga· 2 days agoGilead Sciences and Arcus Biosciences report sustained efficacy and safety in the Phase 2 EDGE-Gastric study for upper GI cancers, showing improved progression-free ...
Hedge Funds are Bullish on This Gene Therapy Stock
Insider Monkey via Yahoo Finance· 2 days agoWe recently compiled a list of the 9 Best Gene Therapy Stocks to Buy Now and in this article, we discuss Gilead Sciences, Inc. (NASDAQ:GILD), which is...
Gilead, with approval in sight, shows $4.3B liver disease drug improves outcomes out to 2 years
FierceBiotech· 4 hours agoThe molecule, seladelpar, had already moved the needle in a phase 3 trial by the time Gilead paid...
Gilead's Trodelvy fails to meet main goal in late-stage cancer study
Reuters via Yahoo News· 6 days agoShares of Gilead fell 3.3% in extended trade after the company said the drug did not meet the main...